|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Adjuvant antiviral therapy for recurrent respiratory papillomatosisChadha NK, James AL
Bookmark this:
     more ...
SummaryThe review found no good quality trials demonstrating the effectiveness or otherwise of antivirals in recurrent respiratory papillomatosisRecurrent respiratory papillomatosis (RRP) is a condition in which wart-like growths occur in the upper airway of children or adults. This can cause difficulty in breathing or a change in voice. This condition is usually treated by repeated surgery to remove these "warts", but it has been proposed that additionally using antiviral medications may help this condition. This review found no trials of good quality to demonstrate that antivirals are effective in recurrent respiratory papillomatosis. Well-designed studies are needed.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2008 Issue 3, Copyright © 2008 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
October 19. 2005 AbstractBackgroundRecurrent respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the upper airway. It can affect both adults and children causing airway-obstruction and voice change. Treatment usually involves repeated surgical debulking of the papillomata, and several agents have been proposed as adjuvants to surgical debulking. These include antivirals, administered systemically or injected into the lesions. ObjectivesTo assess the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children and adults. Search strategyWe searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3, 2004), MEDLINE (January 1966 to November 2004), and EMBASE (January 1985 to November 2004) in December 2004. We checked reference lists of articles, contacted pharmaceutical companies and contacted leading experts in the field for further studies. Selection criteriaAll randomised controlled trials. Data collection and analysisOne hundred references were identified from the searches. Twenty-five were appropriate for retrieval and assessed for eligibility by the authors. None met the inclusion criteria. Main resultsNo controlled trials were identified. Authors' conclusionsThere was insufficient evidence from controlled trials on which to base reliable conclusions about the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis. Further research is required before any specific antiviral adjuvant therapy can be recommended. |